TacticScaleWhat Sarepta Therapeutics Does & How It Makes Money (SRPT)
Updated October 2026 · reflects Sarepta Therapeutics's latest reported financials
Biotech developing genetic medicines for Duchenne and other rare diseases. Sarepta earns revenue mainly from selling its approved Duchenne therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS), and it also has collaboration and license agreements with partners such as Roche and Arrowhead.
How Sarepta Therapeutics makes money
Sarepta earns revenue mainly from selling its approved Duchenne therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS), and it also has collaboration and license agreements with partners such as Roche and Arrowhead.
What Sarepta Therapeutics does
Sarepta Therapeutics is a commercial-stage biotech based in Cambridge, Massachusetts, focused on genetic medicines for rare diseases. Its core franchise is Duchenne muscular dystrophy. It sells three exon-skipping drugs (EXONDYS 51, VYONDYS 53 and AMONDYS 45), each for patients with specific dystrophin gene mutations, plus ELEVIDYS, an AAV-based gene therapy. Its pipeline includes SRP-9003, a gene therapy for limb-girdle muscular dystrophy type 2E (LGMD2E), and two RNAi programs in Phase 1/2a trials: SRP-1001, which targets DUX4, and SRP-1003, which reduces DMPK gene expression. It works with partners including Roche, Arrowhead Pharmaceuticals, Nationwide Children's Hospital, Hansa Biopharma, the University of Western Australia and Duke University.
Products & services
- ELEVIDYS
- EXONDYS 51
- VYONDYS 53
- AMONDYS 45
- SRP-9003
- SRP-1001
What is Sarepta Therapeutics worth?
On an owner-earnings DCF, Sarepta Therapeutics's most-likely value is about $36 versus a recent price near $18 (100% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$24) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $18 is below even the no-growth floor ($24); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -3.3%/yr. A bargain only if that pessimism is overdone.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
PTC Therapeutics (PTCT) · BioMarin Pharmaceutical (BMRN) · Vertex Pharmaceuticals (VRTX) · Krystal Biotech (KRYS) · Seres Therapeutics (MCRB)